Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.

Saved in:
Bibliographic Details
Title: Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.
Authors: Ngoi NYL; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Choi CH; Samsung Medical Center, Seoul, South Korea., Zhu J; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore., Lim D; Department of Pathology, National University Health System, Singapore, Singapore., Tan TZ; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore., Sun H; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore., Heong V; Department of Medical Oncology, Tan Tock Seng Hospital, Singapore, Singapore., Ow SGW; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Chay WY; Division of Medical Oncology, National Cancer Centre, Singapore, Singapore., Kim HS; Seoul National University Hospital, Seoul, South Korea., Lim YW; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Lim SE; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Goss G; Department of Oncology, Box Hill Hospital, Box Hill, Australia., Goh JC; Royal Brisbane and Women's Hospital, Brisbane, Australia., Kim JW; Seoul National University Hospital, Seoul, South Korea., Friedlander M; Prince of Wales Clinical School, University of New South Wales, Prince of Wales Hospital, Sydney, Australia., Tai BC; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore., Kim K; Seoul National University Bundang Hospital, Seongnam-Si, South Korea., Tan DSP; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Sep 15; Vol. 31 (18), pp. 3907-3915.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-0201